• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agency of Health Technology Assessment of Uruguay
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Healthcare Quality Institute
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24897 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with deep vein thrombosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Annual Report 2010. German version.]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Anti-GD2 immunotherapy in patients with high risk neuroblastoma]
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-Heparin/Platelet Factor 4 antibody assey]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Anti-immunoglobulin E (omalizumab) for the treatment of allergic asthma in adults]
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-saccharomyces cerevisiae antibody test]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Antibiotic prophylaxis in digestive tract and abdominal wall surgery]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Antibiotic therapy in hospital, oral versus intravenous treatment]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibiotic therapy: Does a shorter duration of administration lead to comparable treatment results?]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Antibodies to pgp9.5 in small fiber neuropathy]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-coated drug-eluting stents for treatment of coronary artery stenosis]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anticonvulsants: Evidence report for the S3 guideline on the definition, causes, diagnosis and treatment of fibromyalgia syndrome]
2010     Canary Health Service [Antidepressant drugs and psychological treatments for depressive disorders: an economic review and evaluation]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Antigermix – disinfection of endocavitary ultrasonography probes]
2020     National Committee for Technology Incorporation (CONITEC) [Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Antipsychotic polypharmacy in the treatment of schizophrenia]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Antithrombotic treatments following heart valve replacement surgeries]
2009     Committee for New Health Technology Assessment (CNHTA) [Antroduodenal manometry]
2027     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety and panic disorder: do those affected benefit from the "emotional freedom technique”?]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety disorders: does the complementary use of eye movement desensitization and reprocessing (EMDR) therapy as a psychotherapeutic approach lead to better results?]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Aortic valve replacement with rapid deployment or sutureless valves]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Addendum to Commission A19-09]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2010     Committee for New Health Technology Assessment (CNHTA) [APC gene,mutation[sequencing]]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Applicability of sentinel-lymph-node detection and biopsy in the treatment of vulval cancer]
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2011     Andalusian Health Technology Assessment Area (AETSA) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Application of the INESSS framework : assessing the value of digital technologies in health and social services]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Appraisal of the variability and suitability of prescribing antimicrobials in primary health care in the Basque Country]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Approach to personality disorders in the mental health system of the Basque Country]
2023     Andalusian Health Technology Assessment Area (AETSA) [Appropiate indication for leadless pacemaker. Systematic review and appropriateness criteria]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of cardiac monitoring in the emergency department]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in acute abdominal pain]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in primary and secondary care : ultrasonography in breast pathology]
2005     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of Factor VIII for treatment of hemophilia - A consensus conference]
2000     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of Factor VIII in the treatment of haemophilia. A Literature review and opinions of an expert panel on the correct use of different preparations of Factor VIII]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - 25-OH vitamin D testing]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - aspartate aminotransferase testing in the investigation of liver injury]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - bleeding time (in vivo)]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests - direct bilirubin testing]
2026     Institut national d'excellence en sante et en services sociaux (INESSS) [Appropriate use of laboratory tests – (1-3)-β-D-glucan serum testing]
2009     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of recombinant activated factor VII in nonhaemophilic patients]
2009     Andalusian Health Technology Assessment Area (AETSA) [Appropriateness criteria for vertebral arthrodesis]
2009     Canary Health Service [Appropriateness in the indication of physical therapy techniques for cervical pain, low back pain and chronic shoulder pain of non-specific origin]
2025     Haute Autorite de sante (HAS) [Appropriateness of prescribing erythrocyte sedimentation rate (ESR) – are there any remaining?]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies : appropriate admission explicit criteria for heart failure (HF)]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Development of appropriateness explicit criteria for carotid revascularization]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Efficacy and safety of pharmacological treatment for bipolar disorder]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Systematic review of the admission criteria in acute decompensated heart failure]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Aquapheresis – ultrafiltartion for congestive heart failure]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy, 1 to 3 years) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy) - Addendum to Commission A21-135]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V]
2015     The Swedish Council on Health Technology Assessment (SBU) [Arginine and caries prevention]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Argon plasma coagulation for gastrointestinal lesions]
2017     Canary Health Service [Argus II. Retinal Prosthesis System]
2014     The Swedish Council on Health Technology Assessment (SBU) [Aromatase inhibitors for early-stage breast cancer]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aromatase inhibitors in female breast cancer]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Arrhythmia ablation by EnSite NavX electroanatomical mapping]
2024     Agency of Health Technology Assessment of Uruguay (AETSU) [Arsenic trioxide for the treatment of acute promyelocytic leukemia]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Art therapy: visual arts in the management of mild cognitive impairment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Arterial stiffness measurement for cardiovascular risk classification in high blood pressure patients]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Arthrofibrosis (excessive scarring) in the knee: can surgical procedures reduce movement restrictions and pain?]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Arthroplasty register for Germany]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Arthroplasty register for Germany]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Arthroscopy of the knee joint for gonarthrosis]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Arthroscopy with joint washout in the treatment of knee arthrosis]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Artificial disc replacement]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence for the detection of colorectal precancerous lesions in colonoscopy]
2024     HTA South [Artificial intelligence in breast cancer screening with mammography]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Artificial intelligence in medical imaging: fields of application and considerations for its deployment in Quebec]
2026     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence software to detect viable tissue in stroke patients on CT or perfusion MRI of the skull]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for acute myocardial infarction using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for paroxysmal atrial fibrillation using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based screening test for emergent large vessel occlusion using non-contrast brain CT images]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Artificial liver support systems]
2022     Canary Health Service [Artificial pancreas with dual release of insulin and pramlintide for treatment of type 1 diabetes mellitus]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Artificial urinary sphincter in pediatric patients]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Artificial urinary sphincter post-prostatectomy]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]